Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pra Health (PRAH)

Pra Health (PRAH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,704,781
  • Shares Outstanding, K 64,795
  • Annual Sales, $ 3,183 M
  • Annual Income, $ 197,040 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.33
  • Price/Sales 3.42
  • Price/Cash Flow 27.11
  • Price/Book 6.88
  • Price/Earnings ttm 38.71
  • Earnings Per Share ttm 4.34
  • Most Recent Earnings $1.35 on 04/28/21
  • Next Earnings Date 08/05/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 1.24
  • Number of Estimates 3
  • High Estimate 1.26
  • Low Estimate 1.22
  • Prior Year 0.69
  • Growth Rate Est. (year over year) +79.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
164.28 +0.57%
on 06/30/21
172.43 -4.19%
on 06/01/21
-5.71 (-3.34%)
since 05/28/21
3-Month
151.77 +8.86%
on 04/01/21
175.95 -6.10%
on 05/25/21
+11.45 (+7.45%)
since 03/30/21
52-Week
93.00 +77.65%
on 07/14/20
175.95 -6.10%
on 05/25/21
+67.92 (+69.81%)
since 06/30/20

Most Recent Stories

More News
Veradigm and PRA Health Sciences Partner to Create the Industry’s Leading EHR-Based Clinical Research Network

Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), and PRA Health Sciences, Inc. (NASDAQ: PRAH), one of the...

PRAH : 165.21 (-1.67%)
MDRX : 10.9500 (+4.19%)
Veranex Announces Investment From Summit Partners to Form Comprehensive Concept-to-Commercialization Medtech Services Company

Veranex today announced the formation of the first concept-to-commercialization global service provider dedicated to the medtech industry. Formed in partnership with global growth investor Summit Partners...

PRAH : 165.21 (-1.67%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds BMTC, RBC, PRAH, and MNR Shareholders About Its Ongoing Investigations

NEW YORK, May 28, 2021 (GLOBE NEWSWIRE) --

BMTC : 45.01 (-1.57%)
RBC : 323.36 (-0.34%)
PRAH : 165.21 (-1.67%)
MNR : 16.55 (+0.61%)
Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors

Strengthening Board of Directors with Expertise in Innovative Product Launches

TMDX : 78.43 (+1.59%)
PRAH : 165.21 (-1.67%)
AVXL : 8.53 (+0.59%)
PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma

Pharmaceutical, biotech and other research sponsors can now connect their clinical studies to longitudinal real-world data – speeding up drug development and aligning with the 21st Century Cures Act....

PRAH : 165.21 (-1.67%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates KSU, PMBC, PRAH, WRI; Shareholders are Encouraged to Contact the Firm

NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

KSU : 293.59 (-1.69%)
PMBC : 9.40 (-1.16%)
PRAH : 165.21 (-1.67%)
WRI : 31.44 (-2.06%)
PRA HEALTH SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of PRA Health Sciences, Inc. - PRAH

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of PRA Health Sciences, Inc. (NasdaqGS: PRAH)...

PRAH : 165.21 (-1.67%)
ICLR : 207.65 (+1.95%)
PRA Health Sciences, Inc. Reports First Quarter 2021 Results

RALEIGH, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (“PRA,” "we," "us" or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter ended March 31,...

PRAH : 165.21 (-1.67%)
PRA Health Sciences expands its response to COVID-19 with pharmacovigilance solutions for authorized vaccines and therapeutics

PRA offers post-authorization safety solutions to keep up with the speed of COVID-19 vaccine and therapeutic pharmacovigilance requirements

PRAH : 165.21 (-1.67%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates COHR, BPFH, TPCO, PRAH; Shareholders are Encouraged to Contact the Firm

NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

COHR : 105.88 (+2.42%)
BPFH : 14.75 (+0.07%)
TPCO : 17.26 (+0.41%)
PRAH : 165.21 (-1.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology...

See More

Key Turning Points

3rd Resistance Point 172.37
2nd Resistance Point 170.56
1st Resistance Point 167.89
Last Price 165.21
1st Support Level 163.41
2nd Support Level 161.60
3rd Support Level 158.93

See More

52-Week High 175.95
Last Price 165.21
Fibonacci 61.8% 144.26
Fibonacci 50% 134.48
Fibonacci 38.2% 124.69
52-Week Low 93.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar